No abstract

Purpose: To observe changes in the papillomacular nerve fiber bundle (PMB) after pars plana vitrectomy (PPV) in patients with idiopathic epiretinal membrane (iERM) and to compare the surgical outcomes of PPV with and without air tamponade. Methods: From 2015 to 2017, medical records were retrospectively analyzed for patients who had received at least one year of follow-up after vitrectomy with iERM. Results: A total of 89 patients with 89 eyes were included in the study. In both groups (group with and without air tamponade) the mean best-corrected visual acuity (BCVA) after surgery improved significantly from 3 months to 1 year after surgery compared with preoperatively. The thickness of the PMB tended to increase gradually a month post-surgery; however, it showed a decline 3-months and 1-year post-operatively. The PMB thickness significantly increased until 6 months after surgery compared with the thickness of the opposite eye, but gradually decreased, and there was no significant difference at 1 year after surgery. There was no significant correlation between the thickness of the PMB and BCVA at 1 year postoperative. No difference between BCVA and PMB thickness was noted between the two groups at any point before or after the surgery. Conclusions: After vitrectomy in patients with iERM, PMB thickness increased temporarily and subsequently decreased, showing a significant difference at 3-months and 1-year post-surgery. However, PMB thickness did not show a significant difference compared with that of the opposite eye. BCVA improved significantly compared to its preoperative status, but there was no significant correlation between PMB thickness and BCVA 1-year postoperatively. Air tamponade did not significantly affect changes in visual acuity and PMB thickness during the 1 year postoperatively.

Purpose: To evaluate the short-term ophthalmic side effects of bilateral same-day intravitreal bevacizumab injections. Methods: We retrospectively analyzed patients who underwent intravitreal bevacizumab injection in both eyes on the same day from January 2015 to June 2019. The patients were followed up at 1 day, 1 week, and 1 month after the injection. Results: A total of 281 patients (153 males and 128 females) and 562 eyes were included in the study, and 950 bilateral same-day intravitreal bevacizumab injections were performed. The mean age of patients was 58.87 ± 13.44 years. The most common cause of bilateral injection was that of complications due to diabetic retinopathy, which accounted for 66.3%, followed by age-related macular degeneration at 22.2%, retinal vein occlusion at 5.1%, and central serious chorioretinopathy at 2.1%. There were 0 cases of endophthalmitis after 950 injections, 13 cases of subconjunctival hemorrhage, and 17 patients with a temporary elevation of intraocular pressure. There were 11 patients with acute intraocular inflammation after bilateral injection, but none in both eyes. Patients with acute intraocular inflammation were followed up at short-term intervals until they improved. All patients showed complete improvement within 2 weeks after injection. Comparing the patients' condition before and after injection, visual acuity improved (p < 0.001). Conclusions: In terms of the frequency of short-term ophthalmic adverse events, bilateral same-day intravitreal bevacizumab injection is a safe procedure with fewer side effects and is more convenient for both the patient and the doctor.

No abstract